Additional insights into oxidative stress biomarkers and in vivo antioxidant assessments are available in recent studies (Mandal et al., 2022
[Reference for naltrexone's role in appetite/reward pathways at higher LDN doses] 6
However, CB-839 in combination with other agents targeting multiple mechanisms may provide an additional strategy to overcome the metabolic adaptations in CLL
We identified 13 MRS studies reporting on the reproducibility of GSH measurement in young or young to middle-aged healthy adults (Bednak et al., 2015, Dhamala et al., 2019, Gonen et al., 2020, Lally et al., 2016, Lim and Xin, 2022, Prinsen et al., 2017, Prisciandaro et al., 2020, Reid et al., 2022, Schubert et al., 2017, Terpstra et al., 2005, van de Bank et al., 2015, Wijtenburg et al., 2014, Wijtenburg et al., 2019) (Table 1), using different magnetic field strengths (i.e., 3T, 4T or 7T)